Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
about
Azithromycin and the risk of cardiovascular deathQTc prolongation by psychotropic drugs and the risk of Torsade de PointesTorsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across EuropeStandardizing adverse drug event reporting dataDrug safety data mining with a tree-based scan statistic.Data mining of the public version of the FDA Adverse Event Reporting SystemTriptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database.Estimating causal effects in observational studies using Electronic Health Data: Challenges and (some) solutionsAssessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database.Use of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study.Cardiovascular effects of drugs used to treat Alzheimer's disease.Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System.Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reportsSystems pharmacology of arrhythmiasAntipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database.Clinical use of antidepressant therapy and associated cardiovascular riskPotential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study.The Impact of Opioids on Cardiac Electrophysiology.Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study.Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions.Improving the reporting of adverse drug reactions in the hospital setting.Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.A comparison of the risk of QT prolongation among SSRIs.Azithromycin and the risk of cardiovascular complications.Effect of statins on blood pressure: Analysis on adverse events released by FDA.Cases of drug-induced Torsade de Pointes: a review of Belgian cases in the EudraVigilance database.Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors.Development of an automated assessment tool for MedWatch reports in the FDA adverse event reporting system.Use of an entacapone-containing drug combination and risk of death: Analysis of the FDA AERS (FAERS) database.Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review.Digoxin-induced anemia among patients with atrial fibrillation and heart failure: clinical data analysis and drug-gene interaction network.ACMT Position Statement: The Use of Methadone as an AnalgesicOpioid addiction agonist therapy and the QT prolongation phenomenon: state of the science and evolving research questions.Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study.
P2860
Q24604355-36FEB335-D713-44A4-9C1D-F34BDFE8DC70Q27015763-D0AAF3C3-9A61-4AF2-A175-328319B76BC7Q28535299-227BC5BD-4ED9-4513-9A4C-A050DBB73CF9Q28654311-26CB42BF-0640-478F-BC9E-DD6D4868707EQ30604219-15A11A72-3A68-4839-886A-49369890DCCCQ30651235-FC9F2B45-5CC3-4904-8F6E-C44591B6DD79Q30660036-7369771D-D103-4A83-99CD-15511594A3AEQ30803396-87293CF4-06A1-4E38-BA62-8A519652467BQ30830592-CEBB248C-99A3-4249-A8C3-8E583F22575EQ30852962-8A68C012-792A-4A1F-99C4-B3678F892921Q33161031-C7B367B3-3CC4-47AE-8BAA-C8C9982CF79CQ33164224-C1F20223-0454-4FFF-94AA-D796379D6BCCQ33695227-895E4C67-CCD9-4AF6-9E19-FEC24C6BCF25Q33816182-C7B1579D-23B2-46D4-AC48-586673A01A3AQ33912042-C61E30DB-80A0-4754-9256-7490930C6727Q34016220-D75A6593-A01E-46AD-9565-3F9E7120B2E1Q34111154-34992D86-086E-484B-9D5E-D1547FA229B5Q34336897-223C4B03-337C-4265-BBA1-007932EC9502Q35069176-7D92DC40-1D7A-420C-9FB9-18858C4CBEAEQ36184863-00DF1966-2CC6-4E7C-BA4F-909DB712F43AQ36512458-D4399E4E-7F78-40E7-AB45-F3F043FE47F9Q36706808-D6AB6489-37E4-4F11-81B2-28FA074235A0Q36728665-9C4BBDA5-0812-4B90-B945-03CC718D53D0Q36761496-6AD36D68-E3FF-4FF4-B4BC-B21F67486E57Q37009469-28A861B1-F636-4D00-B1A0-9C417FCBF901Q37727223-5D833797-E07E-465C-835B-487848FB6AF0Q37810421-07BDA106-C7EB-4868-9F1E-930CF048CB84Q38118152-8B1D5C05-69A5-4777-81E6-BC8EE43FE4EAQ38164684-CE6FB6E6-0AA4-4391-BC95-433B86D4CD9DQ38265586-7B0D2FFA-C02C-411F-ACCC-992CCBDB3133Q38781141-038CFDB3-F1A3-4835-BAAC-AC911932F678Q38881765-8DF04A53-20DE-423C-8FF6-039CF4D1C3D4Q38920515-C72D08D3-8EAA-4AC0-871B-40536CCCCCACQ39216921-AF4B50B9-C8DE-4CEF-8B56-26A16EA797C7Q39220049-DF6C3D47-3DDD-4745-A9D9-ACD4152C1D17Q40108685-B7E349D8-5988-45BA-8798-078416C16FA8Q41343546-A1B7C022-CEB6-4818-A374-08FDBFA7A3C5Q42748681-970E922C-1904-4E49-BDD4-42DA507D578CQ43714733-BF3AF4D2-F125-41C3-B446-265E43BDB93DQ43901924-11BDC4C3-3B8C-49C1-91B4-7F9862D18163
P2860
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Drug-induced torsades de point ...... Event Reporting System (AERS).
@ast
Drug-induced torsades de point ...... Event Reporting System (AERS).
@en
type
label
Drug-induced torsades de point ...... Event Reporting System (AERS).
@ast
Drug-induced torsades de point ...... Event Reporting System (AERS).
@en
prefLabel
Drug-induced torsades de point ...... Event Reporting System (AERS).
@ast
Drug-induced torsades de point ...... Event Reporting System (AERS).
@en
P2860
P50
P356
P1476
Drug-induced torsades de point ...... Event Reporting System (AERS).
@en
P2093
Ugo Moretti
P2860
P304
P356
10.1002/PDS.1746
P577
2009-06-01T00:00:00Z